Phase III
ARRC Trial
- Study HIC#:2000031702
- Last Updated:08/12/2024
The proposed study will be a randomized, double-blinded, placebo-controlled Phase III trial to examine the efficacy of AZM therapy relative to placebo in reducing RSV-related morbidity. Patients will be recruited during acute hospitalization and admission to the ICU at seven pediatric hospitals.
- Age2 years and younger
- GenderBoth
Contact Us
For more information about this study, including how to volunteer, contact:
Michelle Ecarma, Research Coordinator
- Phone Number: 1-203-785-4651
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
- Admission to the PICU with a confirmed diagnosis of RSV infection. RSV infection is based on a positive nasal swab for RSV fluorescent antibody or via multiplex assay or culture;
- Requiring intensive respiratory support defined as either mechanical ventilation or NIV (BiPAP or CPAP) or HFNC (at >1 L/kg/min of flow)
- Enrollment into the study within 48 hours of ICU admission and placement on intensive respiratory support;
- Onset of RSV-related symptoms must be less than 5 days;
- Age: Neonates-2 years. For those less than 1 week of age, they must have been discharged home from the hospital after their birth.
